Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sulodexide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Alfasigma
Deal Size : Inapplicable
Deal Type : Inapplicable
Endothelial Protection in Post COVID-19 Patients With Sulodexide
Details : Sulodexide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 12, 2022
Lead Product(s) : Sulodexide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Alfasigma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulodexide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Alfasigma
Deal Size : Inapplicable
Deal Type : Inapplicable
Sulodexide in the Treatment of Chronic Primary Venous Disease of the Lower Extremities
Details : Vessel (Sulodexide) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Vascular Diseases.
Product Name : Vessel
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 13, 2021
Lead Product(s) : Sulodexide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Alfasigma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulodexide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Alfasigma
Deal Size : Inapplicable
Deal Type : Inapplicable
Suloexide in the Treatment of Early Stages of COVID-19
Details : Sulodexide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 23, 2020
Lead Product(s) : Sulodexide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Alfasigma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulodexide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Poseidon CRO
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sulodexide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Peripheral Arterial Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 12, 2017
Lead Product(s) : Sulodexide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Poseidon CRO
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulodexide
Therapeutic Area : Hematology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sulodexide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Postthrombotic Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 31, 2015
Lead Product(s) : Sulodexide
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulodexide
Therapeutic Area : Nephrology
Study Phase : Phase IV
Sponsor : ALFA WASSERMANN(BJ) Market Research and Management Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Sulodexide on Albuminuria in Chinese Type 2 Diabetic Patients
Details : Sulodexide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetic Nephropathies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 16, 2011
Lead Product(s) : Sulodexide
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Sponsor : ALFA WASSERMANN(BJ) Market Research and Management Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable